
Acute pancreatitis causes severe inflammation, predisposing patients to thromboembolism, which can be further complicated by heparin-induced thrombocytopenia and thrombosis (HITT). A 47-year-old diabetic male patient with severe acute pancreatitis developed a massive saddle pulmonary embolism. Low-molecular-weight heparin (LMWH) treatment triggered a deep vein thrombosis, and a severe platelet drop (28 × 10 9 /l), confirming HITT. Due to a refractory response to fondaparinux, the patient was successfully switched to direct oral anticoagulation with dabigatran etexilate (150 mg twice daily). This led to rapid platelet normalization and clinical stability. When standard parenteral treatments fail in HITT, direct oral anticoagulants like dabigatran offer an effective alternative strategy.
Thrombophilia is a complex disorder that can result from an imbalance between fibrin formation and fibrinolysis. Although several genetic risk factors have been identified, many cases remain unexplained. The present study explores the potential link between the PAI-14G/5G (rs1799762), tissue-type plasminogen activator (t-PA) intron 8I/D, and the t-PA rs114534719 mutation with the risk of thrombophilia in a southern Iranian population. This case–control study included 96 patients with a clinical predisposition to thrombophilia and 96 age-matched and sex-matched healthy individuals as the control group. Genotyping was performed using the ARMS-PCR technique. The association between the genetic variants and the increased risk of thrombophilia was estimated using logistic regression, and the results were expressed as an odds ratio (OR) with a 95% confidence interval (CI). Statistical analysis revealed no significant differences in the genotypic and allelic frequencies of the PAI-14G/5G ( P = 0.37) and t-PA intron 8I/D ( P = 0.93) polymorphisms between the case and control groups. Regarding the t-PA rs114534719 mutation, all participants in both groups carried the wild-type TT genotype, and the mutant allele (C) was not detected in any sample. Furthermore, logistic regression and combined genotype analysis showed no statistically significant correlation between these variants and the risk of thrombophilia in the studied population. The studied genetic variants of the fibrinolytic system do not appear to be independent risk factors for thrombophilia in southern Iran, and the t-PA rs114534719 mutation appears to be extremely rare in this geographic region.
Pregnant women with hereditary type IIa antithrombin deficiency (ATD) are at significantly increased thrombotic risk. We present the case of a woman with four consecutive pregnancy losses due to venous thromboembolism (VTE), subsequently diagnosed with type IIa hereditary ATD. Type IIa ATD is exceptionally rare. The principal therapeutic challenge lies in the absence of established guidelines regarding optimal anticoagulant selection, dosing strategies, and monitoring approaches for such patients, contributing to treatment failure in her first four pregnancies. The patient was referred to our institution before her fifth conception. Preconception intervention began, and we instituted low-molecular-weight heparin (LMWH) therapy, with dose titration guided by thrombin-antithrombin complex (TAT) and anti-Xa activity levels. This regimen demonstrated safety and efficacy, achieving a maximum nadroparin dose of 10 250 IU twice daily. Under close pharmacotherapeutic monitoring by a clinical pharmacist using this individualized protocol, the patient achieved a successful term delivery and was discharged.
After total knee arthroplasty (TKA), rivaroxaban is often used to prevent venous thromboembolism (VTE), while tranexamic acid (TXA) is used to reduce perioperative bleeding. However, plateau hypoxia may affect coagulation. We assessed whether combined intravenous and intra-articular TXA increases VTE risk in plateau TKA patients. This single-center, prospective, randomized, double-blind, pilot controlled trial was conducted at altitude greater than 3500 m. Fifty unilateral TKA patients were randomized to experimental (intravenous + intra-articular TXA) or control (intravenous TXA alone). All received rivaroxaban for 14 days. Primary outcome was new-onset DVT (deep vein thrombosis) or PE (Pulmonary Embolism) at day 3; secondary outcomes included thromboelastography (TEG) and coagulation parameters at 6 h, 1, 2, and 3 days. No VTE occurred in either group. Nonthrombotic ultrasound findings (intermuscular vein dilation with blood stasis) were observed in 9/25 (36%) of the experimental group and 13/25 (52%) of the control group, with no between-group difference ( P = 0.254). TEG parameters showed no significant differences, except for a transiently lower D-dimer in the experimental group on day 1 ( P < 0.001), though clinical relevance is unclear. Hb and Hct declined less in the experimental group at all time points ( P < 0.05), suggesting reduced blood loss. In plateau TKA patients, adding intra-articular TXA to intravenous TXA did not increase short-term VTE risk. These preliminary findings suggest combined TXA with rivaroxaban may be well tolerated in this population.
Background Immune thrombocytopenia (ITP) is a common autoimmune bleeding disorder characterized by decreased platelet counts due to immune-mediated destruction. Recently, the role of the human leukocyte antigen (HLA) has been highlighted in the pathogenesis of autoimmune diseases, such as ITP. However, the specific impact of the two HLA alleles, HLA-DRB1*04 and HLA-DQB1*03, on ITP remains unclear. Therefore, this replication study aims to investigate the association between these alleles and ITP, further validating and clarifying the roles of these alleles in Iranian ITP patients. Methods Fifty ITP patients and 50 healthy individuals were selected. Then, the genotyping of HLA-DQB1*03 and HLA-DRB1*04 was checked using the Sequence Specific Primer-PCR (SSP-PCR) technique. Results The patient group showed significantly lower PLT, Hb, HCT, MCH, MCV, and MCHC compared to the control group ( P < 0.05), while MPV and PDW were significantly higher in the patient group ( P < 0.05). The frequencies of both HLA-DQB1*03 and HLA-DRB1*04 alleles in the patient and control groups showed no statistically significant difference (68.0% vs. 58.0%, P = 0.241, and 30% vs. 18%, P = 0.408, respectively). Neither HLA-DQB1*03 nor HLA-DRB1*04 alleles increased the risk of ITP development ( P = 0.301 and 0.163, respectively). In the patient and control groups, there was no significant difference between the frequency of the presence or absence of HLA-DQB1*03 and HLA-DRB1*04 based on gender. Conclusion The HLA-DQB1*03 and HLA-DRB1*04 alleles do not appear to affect the incidence of ITP in the Iranian population. However, larger studies in populations with different genetic backgrounds may provide different results.